Take orally once daily, with or without food. Swallow the tablet whole; do not crush, chew, or split.

Brexpiprazole acts as a partial agonist at D2 and 5-HT1A receptors, and as an antagonist at 5-HT2A and noradrenergic alpha1B and alpha2C receptors. This unique receptor profile contributes to its therapeutic effects.

• •Known hypersensitivity to brexpiprazole or any component of the formulation.

Store at controlled room temperature (20°C to 25°C), excursions permitted to 15°C to 30°C. Protect from moisture and light. Keep out of reach of children.

Symptoms of overdose may include drowsiness, tachycardia, and hypotension. There is no specific antidote. Treatment should be supportive, including airway management, cardiovascular monitoring, and activated charcoal administration.

Pregnancy: Use during pregnancy only if the potential benefit outweighs the potential risk to the fetus. Neonates exposed to antipsychotic drugs during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms. Lactation: Brexpiprazole is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.